Christopher Bosworth, MBA

Managed multiple partnership across various stages of development and commercialization through governance compliance and internal / external strategy alignment 

Key Accomplishments:

• Accelerated China NDA submission by one year, to maintain first-to-market position, by developing inputs with Commercial, Regulatory, ClinOps, and QA leads to persuade big pharma partner to assume significant regulatory risk 

• Avoided unnecessary direct trial costs over $15m plus internal FTE costs by structuring communication plans for internal program team with a strategic partner who exploited ambiguous license agreement terms

• Spearheaded transition of pre-commercial asset to global pharma partner by identifying milestones and activities, developing and managing the program tracker and drafting dashboards and reports for regular working team and leadership meetings

• Accelerated a trial’s first dosing by nine months and avoided $5m in clinical costs by leading an internal assessment with CMC, clinical and regulatory leads and external advisors in response to partner’s manufacturing issues

• Prevented an IND rejection from China’s NMPA by leveraging CMC and regulatory leads and their counterparts in the partner organization to drive technical responses and leadership alignment on strategic decisions

• Reduced program development costs by more than $8m by driving internal alignment among program leads and senior leadership to decline China participation in a global Phase I/II trial conducted by the partner

• Reduced clinical supply costs for an oncology program’s trial by 50% by negotiating a material transfer agreement with US and China BD groups at a big pharma 

Initially led BD function by driving out licensing processes for assets across all phases of development for partnership locally in China and globally. After management transition, added responsibilities for commercial strategy lead and project lead 

Key Accomplishments:

• Drove license agreement final negotiations with US specialty pharma for a Phase III-complete novel biologic addressing the ~$7bn chemotherapy induced neutropenia market

• Led license agreement final negotiations with a big pharma for China rights for Phase III-complete novel biologic addressing China’s $0.8bn chemotherapy induced neutropenia market

• Completed in-licensing processes for multiple cell lines, used in drug discovery and release testing, and a CRO's proprietary technology for a product candidate (now in Phase I trials)

• Supported crossover financing and HKEX IPO processes by drafting sections of the prospectus / A-1 and investor meeting materials, leading investor meetings and managing bakeoff process

• Delivered the TPPs and product positionings for multiple assets by leading three 18+ week market research projects in oncology and inflammation, covering the US, Asian and European markets 

• Sourced and managed acquisition process for large China pharma strategic investor of a US spec pharma business by engaging bankers, conducting strategic analysis, supporting financial analysis and contributing to negotiations 

• Provided the strategy and cross-functional implementation plan for a companion drug delivery device with a three-year budget of ~$5m including market / competitive analysis and multiple use cases 

• Created on-label product differentiation by leveraging data from multiple trials (including meta-analysis), which further directly contributed to pre and post launch publication plans

Member of the China life sciences strategy consulting practice, serving multinational pharma, drug distribution and medical device clients with their China/Asia strategies and Merger and Acquisition execution by executing consulting projects and business development processes

Key Accomplishments:

• Forecasted the market opportunity for a novel drug in four Asian markets with potential peak sales nearing $80m through primary and secondary research and by modeling epidemiology data

• Developed new business models for an MNC drug distributor in China, potentially increasing revenue by 300% in 5 years by shifting from specialty medications to pharmacy solutions

• Supported the APAC region in the global integration of two medical device companies by tracking synergies of $21.3m and identifying $1.8m in additional synergies 

• Managed the Program Management Office to spin out a multinational technology company’s $2.3bn China division and integration in to a major Chinese technology company

Managed biotech fund-of-fund portfolio by drafting investment theses, monitoring calls and distributions and drafting regular LP reports. Supported direct investment initiatives

Key Accomplishments:

• Spearheaded China-focused initiatives for fund-of-fund portfolio companies by identifying and engaging strategic partners, investment targets and Chinese investors

• Supported existing direct biotech investments through BoD representation by engaging counterparts in investment syndication, drafting fundraising materials and creating financial models